Unique ID issued by UMIN | UMIN000013525 |
---|---|
Receipt number | R000015776 |
Scientific Title | Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind, randomized controlled trial |
Date of disclosure of the study information | 2014/04/01 |
Last modified on | 2014/04/03 19:47:31 |
Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind, randomized controlled trial
SAKANA for relieving depression in patients taking escitalopram (Sardine study)
Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind, randomized controlled trial
SAKANA for relieving depression in patients taking escitalopram (Sardine study)
Japan |
major depressive disorder
Psychiatry |
Others
NO
The aim of this study is to examine the efficacy of augmentation of omega-3 fatty acid with escitalopram in patients with major depressive disorder.
Efficacy
Confirmatory
Pragmatic
Hamilton Raing Scale for Depression[Time frame: 12 weeks]
MADRS
SDS
BDI
QIDS-J
CGI-S
RS-14
Serum BDNF, proBDNF, MMP-9, fatty acid level
Plasma IL-6
Interventional
Parallel
Randomized
Double blind -all involved are blinded
Placebo
YES
YES
Central registration
2
Treatment
Food |
Omega-3 Polyunsaturated fatty acid
placebo
20 | years-old | <= |
65 | years-old | >= |
Male and Female
1. The subject did not receive any antidepressant drugs(≥4 weeks at minimal effective dose) for major depression
2. Total HDRS-17 score ≥17
3. The major depressive episode is the focus of the treatment and the treating physician has judged escitalopram to be its appropriate 1st line drug
4. A native Japanese speaker
5. The participant is able to understand and sign written informed consent.
1. History of schizophrenia, schizoaffective disorder or bipolar disorder (DSM-IV) as judged by treating physician.
2. Current dementia, borderline personality disorder, eating disorder or substance dependence (DSM-IV) as judged by treating physician.
3. Imminent high risk of suicide as judged by treating physician.
4. Use of antipsychotic drugs and antidepressant drugs within 1 week of the visit
5. Physical diseases which may contraindicate treatment with escitalopram.
6. Currently pregnant or breast-feeding women
7. Regular consumption of polyunsaturated fatty acid supplements within the last 3 months
8. A habit of eating fish >= 4 times per week, to ensure comparability to patients studied in Western countries.
60
1st name | |
Middle name | |
Last name | Wakako Nakano |
University of Occupational and Environmental Health
Department of Psychiatry
1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan
093-691-7253
wakako-u@med.uoeh-u.ac.jp
1st name | |
Middle name | |
Last name | Wakako Nakano |
University of Occupational and Environmental Health
Department of Psychiatry
1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan
093-691-7253
wakako-u@med.uoeh-u.ac.jp
University of Occupational and Environmental Health
University of Occupational and Environmental Health
National Center of Neurology and Psychiatry
University of Toyama
Tohoku Medical Megabank Organization, Tohoku University
Tohoku Fukushi University
Hakatachikushiguchi cocoro clinic
NO
2014 | Year | 04 | Month | 01 | Day |
Unpublished
Open public recruiting
2014 | Year | 03 | Month | 25 | Day |
2014 | Year | 04 | Month | 01 | Day |
2014 | Year | 03 | Month | 27 | Day |
2014 | Year | 04 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015776